Exhibit 99.1

Appendix 4C

Quarter Ended 31 March 2014

San Diego, California and Sydney, Australia (Wednesday 30 April 2014, AEST) — REVA Medical, Inc. (ASX: RVA) (“REVA” or the “Company”) is pleased to provide the attached Appendix 4C Quarterly Report for the quarter ended 31 March 2014. The Appendix 4C is unaudited.

First Quarter Highlights

During the first quarter of 2014, the Company’s operating activities focused on:

·                  Completion of clinical enrollment with the ReZolve2 scaffold. The study is being conducted at locations in Australia, Brazil, Europe, and New Zealand. Enrollment in the study was completed 7 January 2014, with a total of 112 patients; and

·                  Development of FantomTM, the Company’s next generation bioresorbable coronary scaffold family. Fantom utilizes REVA’s advanced proprietary polymers that allow for thinner strut thickness, enhanced deliverability, and applicability to a variety of scaffold designs and is planned to be less expensive to manufacture than ReZolve2.

With the successful advancements in Fantom, on 26 March the Company announced that it had positioned its technical resources to focus on the development and testing of Fantom, with the objective to initiate a clinical study in the fourth quarter of 2014. Concurrent with the announcement of Fantom, the Company effected a reduction in its workforce of approximately 45% and affirmed its intention to complete a financing in 2014.

The Company will hold its Annual General Meeting of stockholders in Sydney, Australia, on Tuesday, 13 May 2014 at 10:30 a.m. at the Museum of Sydney. An additional update on operations will be provided at that time. Information regarding audio access to the meeting will be made available approximately 6 May 2014.

Appendix 4C

As of 31 March 2014, the Company’s cash balance was US$13,032,000 and its interest-bearing investments were US$994,000 for a total of US$14,026,000. The current quarter end cash balance reflects a decrease of US$6,197,000 from the 31 December 2013 quarter end balance of US$19,229,000, primarily as a result of expenditures related to normal operating activities and capital equipment purchases of US$216,000.

HEAD OFFICE:  5751 Copley Drive, San Diego, CA 92111 · +1 (858) 966-3000 · +1 (858) 966-3099 (FAX) · www.revamedical.com

AUSTRALIAN OFFICE:  Level 2, Suite 2, 175 Macquarie Street, Sydney, NSW 2000 · +61 2 9229 2700 · +61 9229 2727 (FAX)

ARBN 146 505 777 · REVA Medical, Inc., is a foreign company incorporated in Delaware, USA, whose stockholders have limited liability

REVA Medical, Inc. — ASX Announcement

The Company plans to file its Form 10-Q Quarterly Report (the “Quarterly Report”) with the U.S. Securities and Exchange Commission and with the Australian Securities Exchange on or before 9 May 2014. The Quarterly Report provides financial statements, along with Management’s Discussion and Analysis of Financial Condition and Results of Operations, for the quarter ended 31 March 2014.

About REVA

REVA is a development stage medical device company located in San Diego, California, USA, that is focused on the development, testing, and eventual commercialization of its proprietary bioresorbable stent products, which are also called “scaffolds.” The Company’s technologies combine its stent designs with its proprietary polymer; these products are designed to offer full x-ray visibility, clinically relevant sizing, and a controlled and safe resorption rate. The Company has several products in clinical study phase. A total of 112 patients were enrolled in its most recent trial in Australia, Brazil, Europe, and New Zealand; they will be followed for a total of five years, with primary data to be obtained at nine and 12 months. REVA will require successful clinical results and regulatory approval before it can commercialize any of its products.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management’s beliefs, assumptions and expectations and on information currently available to management. All statements that are not statements of historical fact, including those statements that address future operating performance and events or developments that we expect or anticipate will occur in the future, are forward-looking statements, such as those statements regarding our ability to raise financing to fund our operations on terms favorable to us or at all, our ability to obtain the regulatory approvals, our ability to timely and successfully complete our clinical trials, our ability to protect our intellectual property position, our ability to commercialize our products if and when approved, our ability to develop and commercialize new products, and our estimates regarding our capital requirements and financial performance, including profitability. You should not place undue reliance on these forward-looking statements. Although management believes these forward-looking statements are reasonable as and when made, forward-looking statements are subject to a number of risks and uncertainties that may cause our actual results to vary materially from those expressed in the forward-looking statements, including the risks and uncertainties that are described in the “Risk Factors” section of our Annual Report on Form 10-K filed with the United States Securities and Exchange Commission (the “SEC”) on March 17, 2014. Any forward-looking statements in this announcement speak only as of the date when made. REVA does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

2

Appendix 4C

Quarterly report for entities

admitted on the basis of commitments

Rule 4.7B

Appendix 4C

Quarterly report

for entities admitted

on the basis of commitments

Introduced 31/03/00  Amended 30/09/01, 24/10/05, 17/12/10

Consolidated statement of cash flows

+ See chapter 19 for defined terms.

17/12/2010

1

2

Payments to directors of the entity and associates of the directors

Payments to related entities of the entity and associates of the related entities

Non-cash financing and investing activities

2.1                               Details of financing and investing transactions which have had a material effect on consolidated assets and liabilities but did not involve cash flows

N/A

2.2                               Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest

N/A

Financing facilities available

Add notes as necessary for an understanding of the position.

3

Reconciliation of cash

Acquisitions and disposals of business entities

Compliance statement

1                     This statement has been prepared under accounting policies which comply with accounting standards as defined in the Corporations Act (except to the extent that information is not required because of note 2) or other standards acceptable to ASX.

2                     This statement does give a true and fair view of the matters disclosed.

4

Notes

1.                                     The quarterly report provides a basis for informing the market how the entity’s activities have been financed for the past quarter and the effect on its cash position.  An entity wanting to disclose additional information is encouraged to do so, in a note or notes attached to this report.

2.                                     The definitions in, and provisions of, AASB 107: Statement of Cash Flows apply to this report except for any additional disclosure requirements requested by AASB 107 that are not already itemised in this report.

3.                                     Accounting Standards.  ASX will accept, for example, the use of International Financial Reporting Standards for foreign entities.  If the standards used do not address a topic, the Australian standard on that topic (if any) must be complied with.

5